Erudio Healtherudio.com
Sponsor
QED Therapeutics, a BridgeBio company trials: what clinicians said in public
No HCP commentary report on a trial sponsored by QED Therapeutics, a BridgeBio company yet. Erudio has found public clinician commentary on 3 clinical trials sponsored by QED Therapeutics, a BridgeBio company: CBGJ398X2204, PROOF 301 and PROOF 302. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (QED Therapeutics, a BridgeBio company). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| PROOF 302 NCT04197986 · QED Therapeutics, a BridgeBio company DeepView → | invasive urothelial carcinoma with FGFR3 genetic alterations | Phase 3 | Deep | View | |||
| PROOF 301 NCT03773302 · QED Therapeutics, a BridgeBio company FocusedView → | advanced cholangiocarcinoma with FGFR2 gene fusions/translocations | Phase 3 | Focused | View | |||
| CBGJ398X2204 NCT02150967 · QED Therapeutics, a BridgeBio company FocusedView → | advanced cholangiocarcinoma with FGFR2 fusions or rearrangements | Phase 2 | Focused | View | |||